Module 5: Polypharmacy & Deprescribing Flashcards
1
Q
Geriatric Pharmacokinetics
-Clinical considerations
A
- Renal Funtion
- Calculate CrCl — creatinine is produced in skeletal muscle — If patient is frail, creatinine may appear artifically low d/t underproduction - Albumin
- Poor nutrition may result in low albumin — This will impact protein-bound agents
2
Q
ER visits for ADEs
-Most commonly implicated meds in patients 65+
A
- Warfarin
- Insulin
- Clopidogrel
- Aspirin
- Rivaroxaban
- Lisinopril
3
Q
3 Drug classes implicated in 60% of ED visits for ADEs
A
- Anticoagulants
- Diabetes agents
- Opiod analgesics
4
Q
Prescribing Cascade
A
- Drug 1 — ADE interpreted as new med condition — Drug 2 — ADE interpreted as new med condition — Drug 3
5
Q
Non-Adherence Predictors
A
- Asymptomatic disease
- Inadequate follow-up
- Patient’s lack of insight of value of treatment
- Missed appointments/transportation difficulties
- Poor provider-patient relationship
6
Q
Interventions to improve drug compliance
A
- Medication reviews and counseling to identify barriers, simplify regiemns, and provide education is MOST EFFECTIVE
- Telephone reminders
- Reminder charts and calandars are LEAST effective
- Interactive technology to supervise, remind and monitor adherence — Limited analysis
- Involve a caregiver
- Utilize a medication tray
7
Q
Deprescribing Definition
A
- A Systematic process of identifying and discontinuing drugs in instances in which existing or potential harms outweigh existing or potential benefits w/in the context of an individual patient’s care goals, current level of functioning, life expectancy, values, and preferences
8
Q
Identifying Medications for Discontinuation
A
- Ineffective
- No current indication
- Sx’s have resolved
- Prescribing cascade
- Unacceptable tx burden and/or risk of harm
- Unlikely to confer benefit over patient’s lifespan
9
Q
Scott’s Conceptual Framework?
A
- Ascertain all drugs the patient is currently taking and reasons for each
- Consider overall risk of drug-induced harm in indivisdual patients in determining the required intensity of deprescribing intervention
- Assess each drug for eligibility to be discontinued
- Prioritize drugs for discontinuation
- Implement and monitor drug discontinuation regimen